Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Hypoglycemia and Glucagon01:15

Hypoglycemia and Glucagon

337
Without prolonged fasting, healthy individuals maintain blood glucose levels above 3.5 mM due to a well-adapted neuroendocrine counterregulatory system that effectively prevents acute hypoglycemia, a potentially life-threatening condition. The primary clinical scenarios for hypoglycemia encompass diabetes treatment, inappropriate production of endogenous insulin or insulin-like substances by tumors, and the use of glucose-lowering agents in non-diabetic individuals. Notably, hypoglycemia in the...
337
Acute Kidney Injury V: Interprofessional Care01:20

Acute Kidney Injury V: Interprofessional Care

45
Acute Kidney Injury (AKI) requires a collaborative healthcare approach to restore renal function and prevent complications. Essential management strategies involve monitoring fluid and electrolyte balance, adjusting medications, initiating dialysis when necessary, and providing nutritional support.Fluid and Electrolyte ManagementFluid Monitoring: Regularly monitoring body weight, central venous pressure, and urine output helps detect fluid imbalances early. Patient intake and output are...
45
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

278
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
278
Acute Kidney Injury VI: Nursing Management01:22

Acute Kidney Injury VI: Nursing Management

59
Acute Kidney Injury (AKI) results in an inability to maintain fluid, electrolyte, and acid-base balance. Effective nursing management is critical in improving patient outcomes and includes comprehensive patient assessment and targeted interventions.Comprehensive Patient AssessmentA detailed history collection is essential, focusing on any recent infections, nephrotoxic medication use, or chronic conditions such as hypertension and diabetes that may contribute to AKI. During the physical...
59
Hemodialysis II: Procedure and Complications01:24

Hemodialysis II: Procedure and Complications

133
DialyzersA hemodialysis (HD) dialyzer is a plastic cartridge containing thousands of parallel hollow fibers, which serve as semipermeable membranes. These fibers are typically made from cellulose-based or other synthetic materials. During HD, blood is pumped into the top of the cartridge and distributed among these fibers. Simultaneously, dialysis fluid, known as dialysate, is introduced into the bottom of the cartridge, bathing the outside of the fibers. Across the semipermeable membrane,...
133
Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

262
Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
262

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Anti-diabetic medications to fight Parkinson's disease and dementia with Lewy bodies: a pilot study.

Frontiers in neurology·2026
Same author

Primary hyperparathyroidism due to dual parathyroid adenomas: one orthotopic, one intrathymic in ectopic cervical thymus.

JCEM case reports·2026
Same author

Yttrium-90 radioembolization treatment of metastatic thyroid carcinoma to the liver: a 3-case series.

JCEM case reports·2026
Same author

A Case of Oral Semaglutide for Treatment of Hepatocyte Nuclear Factor 4A Maturity-Onset Diabetes of the Young.

AACE endocrinology and diabetes·2026
Same author

57-Year-Old Man Presenting With Abdominal Pain.

Mayo Clinic proceedings·2026
Same author

Delayed-Onset Amiodarone Induced Thyrotoxicosis After Glucagon-Like Peptide-1 Agonist-Related Weight Loss.

JCEM case reports·2026

Related Experiment Video

Updated: Sep 12, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K

Hypokalemia Requiring Hospitalization After Taking Semaglutide Injections.

Krista N Grennan1, Devina Singh2, Ana-Maria Chindris3

  • 1Internal Medicine, Mayo Clinic, Jacksonville, USA.

Cureus
|August 7, 2025
PubMed
Summary
This summary is machine-generated.

Glucagon-like peptide-1 receptor agonists like semaglutide are not typically associated with hypokalemia. This report details two cases of severe hypokalemia in patients treated with semaglutide, highlighting a potential, albeit rare, adverse effect requiring medical attention.

Keywords:
diabetes type 2drug-induced hypokalemiaglp-1 receptor agonistshypokalemiaobesityweight loss and obesityweight-loss intervention

More Related Videos

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

30.6K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

Related Experiment Videos

Last Updated: Sep 12, 2025

Improving IV Insulin Administration in a Community Hospital
12:08

Improving IV Insulin Administration in a Community Hospital

Published on: June 11, 2012

19.0K
A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings
06:59

A Novel Approach for the Administration of Medications and Fluids in Emergency Scenarios and Settings

Published on: November 9, 2016

30.6K
Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction
05:26

Postconditioning with Lactate-enriched Blood for Cardioprotection in ST-segment Elevation Myocardial Infarction

Published on: May 28, 2019

9.4K

Area of Science:

  • Endocrinology
  • Pharmacology

Background:

  • Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) are widely used for managing type 2 diabetes and obesity.
  • Hypokalemia is not a commonly recognized adverse effect associated with GLP-1 RAs.

Observation:

  • Two female patients, one with type 2 diabetes and another with obesity and prediabetes, developed severe hypokalemia during semaglutide treatment.
  • Patient one experienced recurrent hypokalemia requiring hospitalization, nutritional support, and eventual discontinuation of semaglutide.
  • Patient two, on chlorthalidone and potassium supplementation, developed severe hypokalemia after initiating semaglutide, which resolved after medication adjustment and discontinuation of semaglutide.

Findings:

  • The cases suggest a potential association between semaglutide use and the development of hypokalemia, necessitating careful monitoring.
  • The exact mechanism remains unclear and may be multifactorial, potentially influenced by other medications or patient-specific factors.

Implications:

  • Clinicians should be aware of this potential adverse effect and monitor potassium levels in patients treated with semaglutide, especially those with risk factors for hypokalemia.
  • Further research is warranted to elucidate the relationship between GLP-1 RAs and electrolyte disturbances.